2015
DOI: 10.2147/rru.s55340
|View full text |Cite
|
Sign up to set email alerts
|

Minimally invasive devices for treating lower urinary tract symptoms in benign prostate hyperplasia: technology update

Abstract: Benign prostatic hyperplasia (BPH) represents a spectrum of related lower urinary tract symptoms (LUTS). The cost of currently recommended medications and the discontinuation rate due to side effects are significant drawbacks limiting their long-term use in clinical practice. Interventional procedures, considered as the definitive treatment for BPH, carry a significant risk of treatment-related complications in frail patients. These issues have contributed to the emergence of new approaches as alternative opti… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
6
0

Year Published

2016
2016
2021
2021

Publication Types

Select...
10

Relationship

2
8

Authors

Journals

citations
Cited by 13 publications
(6 citation statements)
references
References 97 publications
0
6
0
Order By: Relevance
“…PAE was first utilized in the 1970s to treat refractory bleeding following prostatic interventions as well as for intractable hematuria 15. It demonstrated a successful reduction in PV without serious complications in human beings in 2010 2.…”
Section: Discussionmentioning
confidence: 99%
“…PAE was first utilized in the 1970s to treat refractory bleeding following prostatic interventions as well as for intractable hematuria 15. It demonstrated a successful reduction in PV without serious complications in human beings in 2010 2.…”
Section: Discussionmentioning
confidence: 99%
“…Several reviews on minimally invasive surgical treatments for lower urinary tract symptoms (LUTS) due to BPH have been published within the last 2 years, perhaps an indication of the interest and progress in this dynamic field of surgical device technology [1] , [2] . Transurethral resection of the prostate (TURP) and open simple prostatectomy (OSP) have been the historical reference-standard procedures for decades.…”
Section: Introductionmentioning
confidence: 99%
“…Prostate cancer (PCa) is the most prevalent cancer type in males >50 years of age and the second most common cause of cancer-associated mortality in males ( 2 ). Benign prostatic hyperplasia (BPH) represents the most common urologic disorder among elderly men, with ~40% of males >60 years affected ( 3 ). Chronic prostatitis/chronic pelvic pain syndromes (CP/CPPS) are other challenging urology disorders responsible for considerable disability in affected patients ( 4 ).…”
Section: Introductionmentioning
confidence: 99%